SIRPA and ovarian cancer: Compared to control, CD47 blockade therapy with SIRPa-Fc decoy receptor (TTI-621) enhanced macrophage-mediated in-vitro phagocytosis of ovarian cancer cells (BRCA1 mutated, UWB1.289 and its counter cell line with BRCA1 wild type, UWB1.289).